Ventricular Arrhythmia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial
This study is open label.Numbers to be randomized (sample size)For Group 1, a sample size of about 2000 SARS-CoV-2-exposed subjects such as household members and/or contacts of COVID-19 patients will take part in the study. Assuming around 1.5-2.0 asymptomatic household members and/or contacts for each COVID-19 patient, we expect to identify approximately 1000-1300 COVID-19 index cases to be randomized. An interim analysis on efficacy is planned using standard alpha-spending function.For Group 2, sufficient power for primary objective (negative swab within 14 days of randomization) will be reached given a sample size of 30...
Source: Trials - July 30, 2020 Category: Research Source Type: clinical trials

Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D
Condition: Heart Failure Interventions: Drug: ACEI/ARB; Drug: ARNI Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 29, 2020 Category: Research Source Type: clinical trials